12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Epanova regulatory update

Omthera submitted an NDA to FDA for Epanova to treat severe hypertriglyceridemia, defined as triglyceride levels >=500 mg/dL. Epanova is an ultra-pure mixture of the free fatty acid forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). AstraZeneca...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >